447 related articles for article (PubMed ID: 21634436)
1. Liposomal drug formulations in the treatment of rheumatoid arthritis.
van den Hoven JM; Van Tomme SR; Metselaar JM; Nuijen B; Beijnen JH; Storm G
Mol Pharm; 2011 Aug; 8(4):1002-15. PubMed ID: 21634436
[TBL] [Abstract][Full Text] [Related]
2. The potential of liposomal drug delivery for the treatment of inflammatory arthritis.
Vanniasinghe AS; Bender V; Manolios N
Semin Arthritis Rheum; 2009 Dec; 39(3):182-96. PubMed ID: 18926560
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
4. The liposomal formulation of doxorubicin.
Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
[TBL] [Abstract][Full Text] [Related]
5. Designing micro- and nano-particles for treating rheumatoid arthritis.
Mitragotri S; Yoo JW
Arch Pharm Res; 2011 Nov; 34(11):1887-97. PubMed ID: 22139688
[TBL] [Abstract][Full Text] [Related]
6. Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis.
Rahman M; Beg S; Anwar F; Kumar V; Ubale R; Addo RT; Ali R; Akhter S
Crit Rev Ther Drug Carrier Syst; 2017; 34(4):283-316. PubMed ID: 29199587
[TBL] [Abstract][Full Text] [Related]
7. Liposomal delivery of photosensitising agents.
Chen B; Pogue BW; Hasan T
Expert Opin Drug Deliv; 2005 May; 2(3):477-87. PubMed ID: 16296769
[TBL] [Abstract][Full Text] [Related]
8. The role of current strategies in the future treatment of rheumatoid arthritis.
Weinblatt ME
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():19-23. PubMed ID: 10646485
[TBL] [Abstract][Full Text] [Related]
9. Immunoliposomes for cancer therapy.
Kontermann RE
Curr Opin Mol Ther; 2006 Feb; 8(1):39-45. PubMed ID: 16506524
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary delivery of insulin by liposomal carriers.
Huang YY; Wang CH
J Control Release; 2006 Jun; 113(1):9-14. PubMed ID: 16730838
[TBL] [Abstract][Full Text] [Related]
11. Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art.
Rahman M; Sharma G; Thakur K; Anwar F; Katare OP; Goni VG; Kumar V; Zamzami MA; Akhter S
Curr Top Med Chem; 2017; 17(2):162-173. PubMed ID: 28093980
[TBL] [Abstract][Full Text] [Related]
12. Role of Liposome Size, Surface Charge, and PEGylation on Rheumatoid Arthritis Targeting Therapy.
Ren H; He Y; Liang J; Cheng Z; Zhang M; Zhu Y; Hong C; Qin J; Xu X; Wang J
ACS Appl Mater Interfaces; 2019 Jun; 11(22):20304-20315. PubMed ID: 31056910
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen in topical liposomes: development, characterization and in-vitro evaluation.
Bhatia A; Kumar R; Katare OP
J Pharm Pharm Sci; 2004 Jul; 7(2):252-9. PubMed ID: 15367383
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting microencapsulation of drugs in liposomes.
Kulkarni SB; Betageri GV; Singh M
J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
[TBL] [Abstract][Full Text] [Related]
15. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
16. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
19. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability of a small unilamellar low-clearance liposomal amikacin formulation after extravascular administration.
Fielding RM; Moon-McDermott L; Lewis RO
J Drug Target; 1999; 6(6):415-26. PubMed ID: 10937287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
